Strides Pharma Science said on Tuesday that its subsidiary has received approval from the US health regulator to market a generic antidepressant medication. The company's Singapore-based wholly-owned subsidiary, Strides Pharma Global Pte Ltd, has received approval for Fluoxetine Tabs (10 and 20 mg) from the U.S. Food & Drug Administration, the drug firm said in a regulatory filing.
The company's product is therapeutically equivalent to Eli Lilly's Prozac tablets.
As per IMS, Fluoxetine tablets have a market size of $23.9 million.
This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of $106 million, the Bengaluru based firm said.
Fluoxetine is used for the treatment of major depressive disorder and obsessive compulsive disorder among others.
RECOMMENDED FOR YOU
India Pharma - IPM Exhibits Recovery In April, After A Dip In March: Motilal Oswal
May 13, 2024
Asian Paints Q4 Results Review - Competitive Intensity To Define Future Course; Maintain Hold: Axis Securities
May 10, 2024
'To The Best Of My Knowledge, Manian Doesn't Have Anything In Hand': Kotak CEO
May 04, 2024
Stride Ventures Raises $165 Million From Diverse Mix Of Investors For Fund III
May 01, 2024
POPULAR